Omega 3 FA Supplements as Augmentation in the Treatment of Depression
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine
(DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety
symptoms in patients with select medical conditions (cancer, cardiovascular diseases and
diabetes).